Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Vaxcyte, Inc.PCVX · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.94 AUCfailure model, filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate0.52% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size bandover $2.67B assetstotal assets $3.0B[1]
Warningsshort runway, thin datanot computable: degenerate inputs, fortress balance sheet
Inputs computable6 of 14
Graded fromfilings received through Feb 24, 2026227 days before the rescan; every figure keyed to the SEC receipt date
Last close$64.992026-10-08; market equity $9.7B; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$40$60NovDecJanFebMarAprMayJunJulAugSepOct$65.02
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Apr 21, 2021nonen/aQ3
Mar 21, 2023nonen/aQ4
Mar 21, 2025nonen/aQ5

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Feb 24, 2026; the document on sec.gov.

We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are re-engineering the way highly complex vaccines are made through the XpressCF™ cell-free protein synthesis platform. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits that are beyond the capabilities of conventional approaches. Vaccines are one of the most successful and cost-effective global health interventions and prevent millions of deaths worldwide each year.

Warnings [top]

Short runway. cash runway is 2.5 months[2]
Thin data. 6 of 14 grade factors are computable; minimum is 7

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 69.4
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(3.4%)[1,3-5](6.6%)69.48112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 27.6
Twelve-month failure probability0.07%0.07%47.82482026-06-30
Altman Z double-prime7.59[1,6-11](0.31)12.67562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
interest expense must exceed $100,000
Current ratio7.91x[6-7]2.96x22.68392025-12-31
Growth and financing, sleeve percentile 31.2
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 0
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three years44.0%[1,5,12-13]2.1%9.47042025-12-31
Net share issuance, one year11.8%[14-15]2.5%53.16342026-02-20

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month68.6%8.0%83hotter than 83 of 100 peers
Distance from 52-week high(11.9%)(31.4%)80closer to its high than 80 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(6.9%)(1.0%)38pricier than 62 of 100 peers
Book value to price0.290.2850pricier than 50 of 100 peers
Sales to pricenot computable0.31required accounting or market input is missing
Composite equity issuance, five years106.4%20.3%79more equity-funded than 79 of 100 peers
Relative strength against the sector, log excess return0.31(0.14)83ahead of 83 of 100 peers

Inputs: market equity $9.7B; EBIT -$923.7M; free cash flow -$669.3M; book equity $2.8B; cash $183.2M[16].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(21.8%)✗ fail[3,5]
Operating cash flow above zero-$655.6M✗ fail[4]
Return on assets improved11.1 pts✓ pass[3,5,12,17]
Operating cash flow exceeds net income$111.1M✓ pass[3-4]
Long-term leverage felln/a[1,5,12]
Current ratio improved(484.6 pts)✗ fail[6-7,18-19]
No new shares issued11.8%✗ fail[14-15]
Gross margin improvedn/a
Asset turnover improvedn/a[5,12]
Cash, filings, liquidity
Cash and equivalents$183.2M[2]
Operating cash flow, four quarters-$881.2M[2,4,20-23]
Months of runway2.5
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing65
10-Q received Aug 5, 2026
Median daily dollar volume$62.9M
63 sessions
Days since newest grade input227

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$3.0B2025-12-312026-02-2410-Kfiling · viewer · series
2cashus-gaap:CashAndCashEquivalentsAtCarryingValue$183.2M2026-06-302026-08-0510-Qfiling · viewer · series
3net incomeus-gaap:NetIncomeLoss-$766.6M2025-12-312026-02-2410-Kfiling · viewer · series
4operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$655.6M2025-12-312026-02-2410-Kfiling · viewer · series
5assetsus-gaap:Assets$3.5B2024-12-312026-02-2410-Kfiling · viewer · series
6current assetsus-gaap:AssetsCurrent$1.6B2025-12-312026-02-2410-Kfiling · viewer · series
7current liabilitiesus-gaap:LiabilitiesCurrent$205.8M2025-12-312026-02-2410-Kfiling · viewer · series
8retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$2.2B2025-12-312026-02-2410-Kfiling · viewer · series
9operating incomeus-gaap:OperatingIncomeLoss-$923.7M2025-12-312026-02-2410-Kfiling · viewer · series
10book equityus-gaap:StockholdersEquity$2.7B2025-12-312026-02-2410-Kfiling · viewer · series
11liabilitiesus-gaap:Liabilities$317.2M2025-12-312026-02-2410-Kfiling · viewer · series
12assetsus-gaap:Assets$1.4B2023-12-312025-02-2510-Kfiling · viewer · series
13assetsus-gaap:Assets$1.0B2022-12-312024-02-2710-Kfiling · viewer · series
14shares outstandingdei:EntityCommonStockSharesOutstanding143,920,3612026-02-202026-02-2410-Kfiling · viewer · series
15shares outstandingdei:EntityCommonStockSharesOutstanding128,761,6222025-02-212025-02-2510-Kfiling · viewer · series
16shares outstandingdei:EntityCommonStockSharesOutstanding148,805,2782026-08-032026-08-0510-Qfiling · viewer · series
17net incomeus-gaap:NetIncomeLoss-$463.9M2024-12-312026-02-2410-Kfiling · viewer · series
18current assetsus-gaap:AssetsCurrent$1.8B2024-12-312026-02-2410-Kfiling · viewer · series
19current liabilitiesus-gaap:LiabilitiesCurrent$140.2M2024-12-312026-02-2410-Kfiling · viewer · series
20operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$513.1M2026-06-302026-08-0510-Qfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$280.6M2026-03-312026-05-0610-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$430.7M2025-09-302025-11-0410-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$287.4M2025-06-302026-08-0510-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.